cardioverter defibrillator

Disclaimer:  While every attempt is made to ensure that drug dosages provided within the text of this journal and the website are accurate, readers are urged to check drug package inserts before prescribing. Views and opinions in this publication and the website are not necessarily endorsed by or reflective of those of the publisher.

The Role of Implantable Cardiac Devices in the Prevention of Sudden Cardiac Death

Vikas Kuriachan, MD, FRCP(C), Fellow, Cardiac Arrhythmia, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB.
Robert Sheldon, MD, PhD, FRCP(C), Professor, Cardiac Sciences, and Associate Dean of
Clinical Research, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB.

The implantable cardioverter defibrillator (ICD) plays an important role in primary and secondary preventions of sudden cardiac death. Several trials conducted in the past few years have shown the superiority of ICDs over drug therapy. Cardiac resynchronization therapy (CRT) is also emerging as an adjunctive treatment for heart failure, with some survival benefits as well. This article reviews the major recent clinical trials of ICD and CRT devices and summarizes their importance in contemporary cardiology.
Key words: cardioverter defibrillator, cardiac resynchronization, older adults, sudden cardiac death, cardiology.